---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-206235"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:45:52.034513+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cytek Q2 revenue up 24% to $49.7M; net loss widens to $4.4M

## Summary
- Revenue $49.7M (+24% YoY); organic revenue $41.5M (+3%) excl. $8.2M from Luminex acquisition.
- Gross margin 57% vs 61% YoY; adjusted gross margin 60% vs 64%.
- Operating loss $9.1M (vs $0.9M loss Q2 2022); net loss $4.4M (vs $0.7M).
- Adjusted EBITDA $1.5M vs $4.8M prior year; cash $298.8M.
- Shipped 100th Cytek Aurora Cell Sorter; FY2023 revenue guidance reaffirmed at $205M-$220M.

## SEC filing metadata
- accession: 0001193125-23-206235
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312523206235/0001193125-23-206235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312523206235/d440092d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-206235
- JSON: https://secwatch.observer/filing/0001193125-23-206235.json
- Plain text: https://secwatch.observer/filing/0001193125-23-206235.txt

## Key facts
- Earnings Releases
  Cytek Biosciences, Inc. reported the second quarter ended June 30, 2023 results: revenue $49.7 million, net income $4.4 million. Guidance reaffirmed.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $49.7 million
  - Net income: $4.4 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Total revenue was $49.7 million, representing 24% growth over the second quarter of 2022 • Total revenue on a non-GAAP constant currency basis was $50.0 million • Organic revenue for Cytek’s existing product
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523206235/0001193125-23-206235-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.